GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects.

"COMPETING INTEREST The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this study."

"This work was supported by ERA PerMed GATA2‐HuMo Funding Mechanism (Spain: Acció instrumental de SLT011/18/00006 of the Department of Health of the Government of Catalonia, to AG and AB; Hungary: ED‐18‐1‐2019‐001 grant from the National Research, Development and Innovation Office to CB; and Germany: German Federal Ministry of Education and Research (BMBF) 2018‐123/01KU1904 to MWW), ÚNKP‐21‐2‐I‐SE‐21 and Hungarian National Academy of Scientist Education grant to KL, TKP2021‐NVA‐15, TKP2021‐EGA‐24 and EU's Horizon 2020 research and innovation programme under grant agreement no. 739593 and Elixir Hungary to CB, MSCA No 101029927‐scGATA2track (H2020‐MSCA‐IF‐2020) to OM‐B, the Spanish Ministry of Economy, Industry, and Competitiveness (MINECO PID2020‐15591RB‐100), La Marató de TV3 (202001‐32), FPS Grant 2018 by Fondazione Pisana per la Scienza ONLUS and CERCA Programme/Generalitat de Catalunya for institutional support to AG, Vera and Joseph Dresner Foundation, Evans MDS Foundation, American Lebanese Syrian Associated Charities, and BMBF MyPred 01GM1911A to MWW. Open access funding enabled and organized by ProjektDEAL."